Empiric Antimicrobial Therapy in Cancer Patients *
|
|
- Jessica Carter
- 6 years ago
- Views:
Transcription
1 Haematology and Blood Transfusion Vol. 29 Modem Trends in Human Leukemia VI Edited by Neth, Gallo, Greaves, Janka Springer-Verlag Berlin Heidelberg 1985 Empiric Antimicrobial Therapy in Cancer Patients * M. T. Browne and P. A. Pizzo A. Introduction The majority of fevers which occur in granulocytopenic cancer patients appear to have an infectious etiology [1]. The practice of initiating empiric antibiotic therapy when the granulocytopenic cancer patient becomes febrile is now well established and has markedly reduced the early morbidity and mortality of infections in these patients. Nonetheless, infections still remain the leading cause of death in neutropenic cancer patients, necessitating refinements in the diagnosis and management of the complications in high risk patients. The impetus for empiric antibiotic therapy in febrile granulocytopenic patients was the early death due to untreated infection (particularly Pseudomonas septicemia) when the granulocytopenic patient became febrile. Indeed, during the late 1960s and early 1970s, 50% of patients with Pseudomonas bacteremia died within 72 hours of their initially positive blood culture [2]. The early initiation of antibiotics significantly reduced this early mortality. Nonetheless, a number of questions regarding the role of empiric antimicrobial therapy for cancer patients in the 1980s can still be asked, including: Who should receive empiric therapy and when should it be started? What constitutes appropriate initial * Pediatric Branch Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA empiric therapy? How should the initial therapy be modified for patients who remain graulocytopenic or who fail to respond to the initial regimen? How long should empiric antibiotics be continued? In dealing with the first question, who should receive empiric therapy and when should it begin, it appears that granulocytopenia is probably the single most important risk factor for infection in cancer patients [3, 4]. Whether or not all granulocytopenic patients require prompt empiric antibiotic management when they become febrile (i.e., patients with solid tumors as well as patients with hematologic malignancies) has been addressed in a number of recent studies. In a survey of 1001 consecutive episodes of fever in 324 pediatric and young adult cancer patients at the NCI, Bethesda, Maryland, there was no apparent difference in the incidence, pattern, or severity of infectious complications that occurred, regardless of the patients' underlying malignancy, once they became granulocytopenic. There were comparable numbers of episodes of fever and granulocytopenia and of documented infections such as sepsis and pneumonia in patients with solid tumors as in those with hematologic malignancies [1]. Similarly, Markmann and Abeloff observed that in adults with solid tumors, early empiric antibiotics were useful in reducing infectious morbidity and mortality [5]. Thus, all granulocytopenic patients, regardless of their underlying cancer, should be considered to be at risk for infection and, once febrile, are candidates for early empiric therapy. The level of granulocytopenia that should prompt empiric ther- 112
2 apy varies in different studies, with some recommending beginning antibiotics when the neutrophil count falls below 1000/mm 3, while most would wait until the neutrophil count is less than 500/mm 3 The rate at which the counts are falling may be as important as the absolute neutrophil number [6]. The degree of fever that should prompt therapy is defined differently at various centers. At the NCI, three oral temperatures above 38 C or one oral temperature over 38.5 C with a granulocyte count less than 500/mm 3 is sufficient to begin empiric therapy. What is most important is for each center to adhere rigidly to predetermined criteria for defining high risk patients. This is particularly important since the diminished inflammatory capability of the granulocytopenic patient can mask the usual signs and symptoms of infection. B. Preantibiotic Evaluation Because untreated infections can be rapidly fatal, it is important that a thorough preantibiotic evaluation be carried out expeditiously. This should include a history and physical examination, at least two sets of preantibiotic blood cultures (if an indwelling line is present, peripheral vein cultures must also be obtained), chest X-ray, urinalysis, urine culture, and aspirate or biopsy cultures from accessible sites suggestive of infection. In spite of such an evaluation, it was not possible to differentiate patients with bacteremia from those with unexplained fever (1] in a recent prospective evaluation of 140 febrile granulocytopenic patients. More than half of the patients with bacteremia in this study lacked any specific physical findings. C. Initial Empiric Antibiotic Combinations Since approximately 85% of the initial pathogens are bacterial, the initial therapy is focused on bacterial pathogens. The original targets of empiric antibiotics were gram-negative bacteria, particularly Pseudomonas aeruginosa, and although gram-negative organisms still predominate, infections due to Pseudomonas have inexplicably declined. In contrast, infections due to gram-positive cocci (i.e., Staphylococcus aureus and Staphylococcus epidermis) have increased in recent years, in part due to the more widespread use of indwelling intravenous catheters (7, 8). In order to give empiric cover for both grani-negative and gram -positive bacteria, broad -spectrum antibiotic therapy is essential. Thus, drug combinations are usually necessary and ideally should be bactericidal and synergistic, with a low potential for organ toxicity. In general, this has usually necessitated a combination of two or three antibiotics. The importance of combination antibiotic therapy has been suggested since patients with gram-negative bacteremia have a greater than 80% survival when their isolate is sensitive to and treated with two antibiotics compared with a survival of 59% when the isolate is sensitive to only one of the two antibiotics [9-11]. In spite of the advantages of combined therapy, drug toxicity (particularly nephrotoxicity) is a concern in the cancer patient who is being exposed to many other toxic drugs. The properties of some of the newer antibiotics raise the possibility of using them as single agents for the empiric management of febrile granulocytopenic patients. For example, in an ongoing study at the NCI, we are comparing monotherapy with ceftazidime (C1Z), a third generation cephalosporin, with our standard threedrug regimen of cephalothin (Keflin), gentamicin, and carbenicillin (KGC). To date, 349 episodes in 212 patients have been randomized to receive either combination therapy with KGC or monotherapy with C1Z when they became febrile and neutropenic «500 polys). The patients have been analyzed according to whether they had a documented infection or whether the etiology of their fever was unexplained. In addition, since the goal of empiric therapy is to protect the patient until results of the preantibiotic cultures are known, it is important to evaluate the efficacy of empiric antibiotic regimens both early in treatment - during the first 72 hours of therapy (i.e., prior to the time that the cause of the fever is 113
3 known), as well as for the entire duration of neutropenia. The success rate in the first 72 hours for both the C1Z- and KGC-treated patients with fevers of unknown origin (FUO) or documented infections was over 97%. In addition, the overall outcome (i.e., at the time of resolution of granulocytopenia) for patients with FUQ was over 98% for both the KGC and C1Z arm, and was comparable for both antibiotic regimens for patients with documented infections. Thus, it would appear that with future advances in antitiotic development, it may be possible to provide effective initial empiric antibiotic management with a single antibiotic in the febrile neutropenic cancer patient. Continued study of this approach is, however, necessary. D. Empiric Antifungal Therapy A second problem is related to patients who remain neutropenic for extended periods and who may be at risk for second infections and superinfections, particularly due to fungi. Because even invasive fungal disease is so difficult to diagnose and because these infections are particularly difficult to treat, especially if the infection has already advanced at the time of diagnosis, an empiric approach to antifungal therapy has also been investigated in high risk patients. Currently, evidence for invasive fungal disease is present in 8%-69% of granulocytopenic patients dying with cancer [12-14]. Persistent fever is often the only indication of an early fungal infection. The major fungal organisms of concern in neutropenic patients are Candida, Aspergillus, Phycomycetes, and Cryptococcus [15]. Blood cultures are rarely of diagnostic help (being positive in fewer than 25 % of cases of disseminated candidiasis and virtually never positive in aspergillosis or mucormycosis) [16]. It is notable that successful therapy of Candida and even Aspergillus has been accomplished when amphotericin B has been instituted very early in the course of the infection [17]. Thus, early empiric antifungal therapy has a rational basis for high risk patients. Several issues are relevant: Who are the patients at high risk? Which antifungal agent should be used? When should it be started and how long should it be continued? Several studies suggest that patients who are persistently neutropenic and febrile in spite of a week or more of antibiotic therapy are at particular risk for developing a fungal infection. Burke et al. utilized empiric amphotericin B in acute leukemia patients experiencing recrudescent fever during empiric therapy with gentamicin and carbenicillin. The incidence of serious fungal infection was found to decrease from 33% to 10% when early empiric antifungal therapy was utilized [18]. In a study at NCI, we addressed the value of empiric antifungal therapy for patients with proven infections who remained febrile and granulocytopenic after 1 week of appropriate antibiotic therapy and who had alimentary tract colonization with Candida. Gastrointestinal colonization was associated with a heightened frequency of disseminated fungal invasion in the postmortem analysis by Young et al. Of the 329 episodes of proven infections we treated between November 1975 and December 1979, 22 (6.7%) had gastrointestinal colonization with fungi while febrile and neutropenic and had amphotericin B added empirically to their antibiotic schedule. It was notable that half of these patients actually defervesced within a median of3 days after starting amphotericin B, despite remaining markedly granulocytopenic. Of the 22 patients, 20 began the amphotericin within 2 weeks after starting antibiotics and continued therapy until the resolution of granulocytopenia. All of these patients recovered, none with evidence of fungal infections [19]. A second study [19] prospectively addressed the issue of using empiric amphotericin B in the granulocytopenic patient with persistent unexplained fever. The question being addressed in this study was whether the persistent fever represented an undiagnosed bacterial infection for which the antibiotic regimen should be modified or whether it represented a secondary infection, perhaps due to fungi. The usual approach in the patient with persistent unexplained fever is either to discontinue anti- 114
4 biotics and reevaluate the patient or to continue the antibiotics in spite of the persistent febrile course. We compared these two approaches with one in which the antibiotics were continued and empiric antifungal therapy was added with amphotericin B. Patients were randomized to one of three groups: I to have their broad spectrum antibiotics (Keflin, gentamicin, carbenicillin) discontinued after 7 days of therapy; II to continue antibiotics until resolution of fever and neutropenia; and III to continue antibiotics along with empiric amphotericin B until the resolution of fever and granulocytopenia. We observed that stopping antibiotics resulted in early complications, predominantly due to bacterial organisms, with 56% of the patients developing complications within a median of 3 days of stopping antibiotics. Continuing antibiotics seemed to prevent early bacterial infection, but 31 % of the patients randomized to this group developed fungal infections. The patients randomized both to continue antibiotics and to receive empiric antifungal therapy appeared to do best in this study. While 1 of the 18 patients in this group did develop a fungal infection, this was with Petriellidium boydii, an organism resistant to amphotericin. Thus, it seems appropriate both to continue antibiotics and to give empiric amphotericin B in the persistently febrile granulocytopenic patient. We have chosen 7 days of persistent fever while the patient is on appropriate antibiotics as the criteria for initiating antifungal therapy, although this decision is somewhat arbitrary. Amphotericin B is the present drug of choice, although we are presently comparing empiric amphotericin B with high dose oral ketoconazole in patients who are persistently febrile and granulocytopenic after 1 week of antibiotics. If no evidence for a fungal infection is found, the empiric antifungal therapy can be discontinued when the patient's granulocyte count recovers. On the other hand, if a fungal infection is documented, a more extended course of therapy is indicated. The dose of amphotericin ranges from 500 mg for an uncomplicated fungemia to 2 g or more when there is evidence of organ involvement or a disseminated infection. Antifungal therapy may also be administered empirically to patients with progressive mucositis and symptomatic esophagitis. Although other organisms, e.g., bacteria, herpes simplex, can cause symptoms of mucositis or esophagitis, patients with Candida lesions will generally improve within a 48 hour trial of empiric amphoteri CIn. E. Duration of Therapy A third problem relates to the duration that empiric treatment with antibiotics and antifungals should be continued, particularly when the initial evaluation has not revealed a documented infection and yet the patient remains granulocytopenic for more than 1 week. In patients with a documented infection who have defervesced on therapy and who do not have a persistent site of infection, our practice has been to continue antibiotics for days. The more difficult situation arises in patients who have no documented source of infection and who remain persistently granulocytopenic' for over I week. Simply continuing empiric antibiotics in these patients without a source of infection must be balanced against superinfections and the risk for organ toxicity. A series of prospective trials at the NCI has addressed this problem by randomizing patients with a FUO either to discontinue their antibiotics or to continue them until the resolution of the granulocytopenia. The patients in these trials were stratified according to whether they had defervesced or remained febrile after the initiation of antibiotics. Within 3 days of discontinuing antibiotics, 41 % of the FUO patients who had initially defervesced became febrile again and the organisms obtained on reevaluation were sensitive to the antibiotics they had previously received. Similarly, 56% of the FUO patients who had remained febrile in spite of antibiotics developed complications (including hypotension in 38%) within 3 days of stopping their therapy [20]. Although patients with persistent fever and granulocytopenia did best when empiric antibiotics were continued and empiric amphotericin was added, nearly half of these patients did well even when anti- 115
5 biotics were stopped. This has led some investigators to suggest that stopping antibiotics may be appropriate, providing the patient can be closely monitored and the antibiotics promptly reinstituted if necessary. However, because reliable end points for reinstituting therapy are vague and because these patients can deteriorate quite rapidly, it is our opinion that it is prudent to continue antibiotics, especially in the persistently febrile patient. Other modifications of therapy may also be required in light of preantibiotic culture results and the patient's clinical response. Common modifications include the addition of vancomycin for S. epidermidis bacteremias and line site infections and the addition of clindamycin for anaerobic coverage in a patient with either perirectal tenderness, necrotizing gingivitis, or a possible abdominal source. The issue of narrowing the patient to pathogen-specific therapy versus continuing the broad spectrum therapy in patients who have microbiologically documented bacteremias and for whom the antibiotic sensitivities are known is also currently being addressed in a prospective randomized trial at the NCI. Thus far, no clear advantage has emerged to either strategem, but this study is ongoing. F. Antiviral Therapy In addition to antibiotics and antifungal drugs, antiviral agents have recently been added to the empiric therapeutic armamentarium. For example, acycloguanosine (Acyclovir) has been shown to reduce the incidence of herpes simplex stomatitis when administered prophylactically to patients undergoing bone marrow transplantation or to patients receiving intensive courses of chemotherapy [21]. Similar protection, however, has not been observed with other important viruses in the immunocompromised host, such as cytomegalovirus (CMV) although the recent observation that CMV pneumonitis may be prevented when patients receive passive immunization with high titer CMVantisera is intriguing [21-24]. G. Diffuse Pulmonary Infiltrates Yet another situation in which emplnc therapy may be advantageous is in the cancer patient with a diffuse interstitial pulmonary infiltrate. In the non-neutropenic cancer patient, the protozoan Pneumocystis carinii is a frequent etiologic agent, carrying a 100% mortality if untreated. Because of the nonspecific signs and symptoms, P. carmll pneumonia is virtually indistinguishable from other etiologic agents causing diffuse interstitial pulmonary infiltrates, including CMV, bacteria (e.g., Legion ella, Mycoplasma), fungi (Candida, Aspergillus, Cryptococcus) and viruses (influenza, RSV, adenoviruses, rhinoviruses, and measles). Prior to the availability of trimethoprim-sulfamethoxazole (TMP / SMX), most clinicians agreed that biopsy confirmation of P. carinii was essential to justify the administration of potentially toxic treatment with pentamidine isothionate. Presently, there is considerable debate as to whether it is preferable to proceed directly to some invasive diagnostic procedure in the patient with a diffuse infiltrate or simply to begin antibiotics empirically and monitor the patient's response to this therapy [25, 26]. However, the appropriate "empiric therapy" can quickly become complicated and can include broad spectrum antibiotics and even antifungal agents in patients who are neutropenic and already on antibiotics when the infiltrate appears. The balance between the potential side effects of broad spectrum therapy and the risks of an invasive diagnostic procedure must be carefully weighed. Presently, at the NCI, we are addressing this issue in a study which randomizes patients with a diffuse interstitial pulmonary infiltrate to either appropriate initial empiric therapy or to an open-lung biopsy and pathogen-specific therapy. If the patient randomized to the empiric therapy arm does not stabilize or improve within 4 days, an open-lung biopsy is then performed as a further guide to therapy. The major question, of course, is whether an invasive procedure can be avoided. To date, 53 patients with diffuse pulmonary infiltrates have been evaluated and 29 have been eligible and randomized. 12 were randomized to immediate open-lung 116
6 biopsy, of whom 8 improved and 4 (33%) died and 17 to empiric therapy, of whom 15 improved and 2 (11.7%) died. Of the 15 patients who had an open-lung biopsy, 12 immediately and 3 after 4 days of therapy, 10 had P. carinii pneumonia, and 5 had nonspecific pneumonitis. Cutaneous T cell lymphoma and Hemophilus injluenzae were diagnosed in addition to P. carinii pneumonia in two patients. Only one patient (with H. injluenzae) had therapy changed as a result of the open-lung biopsy. Therefore, it appears that appropriate empiric therapy may also have a role in cancer patients with diffuse pulmonary infiltrates. Whether new procedures, such as pulmonary lavage, may provide an alternative diagnostic approach is presently being evaluated. In conclusion, major advances have been made in decreasing the morbidity and mortality due to infectious complications in immunocompromised cancer patients with the use of empiric antimicrobial therapy, but refinements of management continue to be necessary. Clinical studies addressing these problems will be extremely helpful in defining appropriate empiric management of these patients. References 1. Pizzo PA, Robichaud KJ, Wesley R, Commers JR (1982) Fever in the pediatric and young adult patient with cancer. Medicine 61: Schimpff SC, Saterlee W, Young VM (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284: Love TJ, Schimpff SC, Schiffer CA et al. (1980) Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med 68: Pizzo PA (1984) Empiric therapy and prevention of infection in the immunocompromised host. In: Mandell G, Douglas G, Bennett J (eds) Principles and practice of infectious diseases, chap 276. Wiley, New York 5. Markman M, Abeloff MD (1983) Management of hematologic and infectious complications of intensive induction therapy for small cell carcinoma of the lung. Am J Med 74: Pizzo PA (1985) Management of infections in cancer patients. In: De Vita VT, Hellman S, Rosenberg SA (eds) Principles and practice of oncology, 2nd edn, chap 55. Lippincott, Philadelphia 7. Wade JL, Schimpff SC, Newman KA et al. (1982) Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 97: Pizzo PA, Ladisch S, Simon R et al. (1978) Increasing incidence of gram-positive sepsis in cancer patients. Med Pediatr Onco15: Davis DB (1982) Bactericidal synergism between B-Iactams and aminoglycosides: mechanisms and possible therapeutic implications. Rev Infect Dis 4: Klastersky J, Zinner SH (1982) Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 4: II. Young LS (1982) Combination or single drug therapy for gram-negative sepsis. In: Remington JS, Swartz MN (eds) Current clinical topics in infectious diseases, vol 3. McGraw-Hill, New York, p Cho SY, Chol HY (1979) Opportunistic fungal infection among cancer patients. Am J Clin Pathol72:617-62l 13. Krick JA, Remington JS (1976) Opportunistic fungal infections in patients with leukemia and lymphoma. Clin Haemotol 5: Singer C, Kaplan MH, Armstrong D (1977) Bacteremia and fungemia complicating neoplastic disease. Am J Med 62: Commers JR, Pizzo PA (1982) The role of empiric antifungal therapy for granulocytopenic cancer patients with persistent fever. In: Klastersky S (ed) Infections in cancer patients. Raven, New York, p Commers JR, Pizzo PA (1983) Empiric antifungal therapy in the management of the febrile-granulocytopenic cancer patient. Pediatr Infect Dis 2: Pennington JE (1972) Aspergillus pneumonia in hematologic malignancy. Arch Intern Med 137: Burke PJ, Braine HG et al.. The clinical significance and management of fever in acute myelocytic leukemia. Johns Hopkins Med J 139: Pizzo PA, Robichaud KJ, Gill FA et al. (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72: Pizzo PA, Robichaud KJ, Gill FA et al. (1979) Duration of empiric antibiotic therapy in granulocytopenic cancer patients. Am J Med 67:
7 21. Wade JC, Newton B et al. (1982) Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double blind trial. Ann Intern Med 96: Winston DJ, Pollard RB (1982) Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 97: Meyers JD, Zaia JA et al. (1983) Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after bone marrow transplantation. Ann Intern Med 98: Hiemenz J, Pizzo PA (to be published) New developments in the etiology, diagnosis, treatment and prevention of infectious complications in patients with leukemia 25. Haverkos HW, Dowling JW, Hakale 1R et al. (1983) Diagnosis of pneumonitis in immunocompromised patients by open-lung biopsy. Cancer 52: Hiatt JR, Ramaning KP (1982) The value of open-lung biopsy in the immunosuppressed patient. Surgery 92:
Treatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationAmphotericin B or Ketoconazole Therapy of Fungal Infections in Neutropenic Cancer Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1987, p. 11-15 0066-4804/87/010011-05$02.00/0 Copyright 1987, American Society for Microbiology Vol. 31, No. 1 or Therapy of Fungal Infections in Neutropenic
More informationComparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia
Comparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia I. Malik ( National Cancer lnsititute, Karachi ) Shaharyar (, Department of Radiotherapy
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationPekka Riikonen. Introduction
Recombinant Human Granulocyte-Macrophage Colony-S timulating Factor in Combination with Antibiotics in the Treatment of Febrile Neutropenia in Children Pekka Riikonen Kuopio University Hospital, Division
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationAilyn T. Isais-Agdeppa, MD*, Lulu Bravo, MD*
A FIVE-YEAR RETROSPECTIVE STUDY ON THE COMMON MICROBIAL ISOLATES AND SENSITIVITY PATTERN ON BLOOD CULTURE OF PEDIATRIC CANCER PATIENTS ADMITTED AT THE PHILIPPINE GENERAL HOSPITAL FOR FEBRILE NEUTROPENIA
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationMANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSP There are no translations available. MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
More informationPotential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections.
In the name of God Principles of post Tx infections 1: Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections. Infection processes can progress
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationCeftizoxime in the treatment of infections in patients with cancer
Journal of Antimicrobial Chemotherapy (98), Suppl. C, 67-73 Ceftizoxime in the treatment of infections in patients with cancer V. Fainstein, R. Bolivar,. Elting, M. Valdivieso and G. P. Bodey Department
More informationHospital-acquired Pneumonia
Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More informationUrinary tract infection. Mohamed Ahmed Fouad Lecturer of pediatrics Jazan faculty of medicine
Urinary tract infection Mohamed Ahmed Fouad Lecturer of pediatrics Jazan faculty of medicine Objectives To differentiate between types of urinary tract infections To recognize the epidemiology of UTI in
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationNeutropenic Fever. CID 2011; 52 (4):e56-e93
Neutropenic Fever www.idsociety.org CID 2011; 52 (4):e56-e93 Definitions Fever: Single oral temperature of 101 F (38.3 C) Temperature 100.4 F (38.0 C) over 1 hour Neutropenia: ANC < 500 cells/mm 3 Expected
More informationReady to answer the questions?
파워포인트문서의제목 Reference 1. IDSA GUIDELINES. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America.
More informationSUPPLEMENT ARTICLE DEFINITIONS
SUPPLEMENT ARTICLE The Infectious Diseases Society of America 2002 Guidelines for the Use of Antimicrobial Agents in Patients with Cancer and Neutropenia: Salient Features and Comments Kenneth V. I. Rolston
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationFever. National Pediatric Nighttime Curriculum Written by Debbie Sakai, M.D. Institution: Lucile Packard Children s Hospital
Fever National Pediatric Nighttime Curriculum Written by Debbie Sakai, M.D. Institution: Lucile Packard Children s Hospital Case 1 4-month-old well-appearing girl admitted for croup and respiratory distress.
More informationInfections in Oncology
Infections in Oncology Early Empiric Antibiotic Therapy for Febrile Neutropenia Patients at Low Risk Kenneth V. I. Rolston, MD, Edward B. Rubenstein, MD, of The University of Texas M.D. Anderson Cancer
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationPneumonia in immunosuppressed patients
Blackwell Science, LtdOxford, UKRESRespirology1323-77992004 Blackwell Science Asia Pty LtdMarch 20049S1S25S29Original ArticlePneumonia in immunosuppressed patientss Kohno et al. Respirology (2004) 9, S25
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationBacterial Isolates from Neutropenic Febrile Pediatric Patients and their Sensitivity Patterns to Antibiotics
Bacterial Isolates from Neutropenic Febrile Pediatric Patients and their Sensitivity Patterns to Antibiotics Pages with reference to book, From 287 To 290 Faizah N. Bhatti,Ikram A. Burney,M. Imran Moid,Tariq
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Febrile Neutropenia. These podcasts are designed to give medical students an overview of key topics in pediatrics. The
More informationFEBRILE NEUTROPENIA CURRENT GUIDELINES FOR CHILDREN Alia Zaidi, MD. St. Jude International Outreach Program
SIOP PODC Supportive Care Education (ICON 2016) Presentation Date: 23 rd January 2016 Recording Link at www.cure4kids.org: https://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p25oti35nt7
More informationInfections in acute leukemia in Indian Children
Journal of College of Medical Sciences-Nepal, 2013, Vol-9, No-1, 40-47 Infections in acute leukemia in Indian Children Original Article B Roy, 1 A Biswas, 2 A Chaterjee, 3 A Pan 4, K Basu 5 1 Associate
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationFebrile neutropenia. Febrile neutropenia. Febrile neutropenia. Febrile neutropenia 1/30/2019. Infection in patients with cancer
Manit Sae-teaw B.Pharm, BCP, BCOP Glad dip in pharmacotherapy Faculty of pharmaceutical sciences Ubon Ratchathani University Fever Oral temperature measurement of 38.3 C (101.0 F) single 38.0 C (100.4
More informationManaging Infection in Cancer Patients and Other Immunocompromised Children
The Ochsner Journal 12:202 210, 2012 Ó Academic Division of Ochsner Clinic Foundation Managing Infection in Cancer Patients and Other Immunocompromised Children Russell W. Steele, MD Division of Infectious
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationSupplemental Online Case Discussion: Febrile Neutropenia
Supplemental Online Case Discussion: Febrile Neutropenia Alison C. Young, Fiona J. Collinson St James s Institute of Oncology, St James s University Hospital, Leeds, West Yorkshire, United Kingdom Case
More informationEvaluation of Febrile Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation
ORIGINAL REPORT Evaluation of Febrile Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation Shahideh Amini 1, Molouk Hadjibabaie 2, Zahra Jahangard-Rafsanjani 1, Asieh Ashuri 3, Hassan
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A AAP. See American Academy of Pediatrics (AAP) Acyclovir dosing in infants, 185 187 American Academy of Pediatrics (AAP) COFN of, 199 204 Amphotericin
More informationInfections in immunocompromised host
Infections in immunocompromised host Immunodeficiencies Primary immunodeficiencies Neutrophil defect Humoral: B cell defect Humoral: Complement Cellular: T cells Combined severe immunodeficiency Secondary
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationFever and neutropenia: the early years
Journal of Antimicrobial Chemotherapy (2009) 63, Suppl. 1, i3 i13 doi:10.1093/jac/dkp074 Fever and neutropenia: the early years Gerald P. Bodey* Department of Infectious Diseases, Infection Control and
More informationAnalysis of Two Types of Granulocyte Transfusions in Patients with Acute Leukemia and Septicemia
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 12, No. 2 Copyright 1982, Institute for Clinical Science, Inc. Analysis of Two Types of Granulocyte Transfusions in Patients with Acute Leukemia and Septicemia
More informationUPDATE ON FEBRILE NEUTROPENIA
UPDATE ON FEBRILE NEUTROPENIA Clinical approach and management Dr.Shafiq A. Alimad Head of medical department at university of science and technology hospital YICID 15-December-2014 INTRODUCTION Cancer
More informationInvasive fungal infections have become an increasing
A Multicenter, Randomized Trial of Fluconazole versus Amphotericin B for Empiric Antifungal Therapy of Febrile Neutropenic Patients with Cancer* Drew J. Winston, MD, James W. Hathorn, MD, Mindy G. Schuster,
More informationPerformance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
DOI 10.1007/s00520-007-0347-3 ORIGINAL ARTICLE Performance of a modified MASCC index score for identifying low- febrile neutropenic cancer patients Luciano de Souza Viana & José Carlos Serufo & Manoel
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationInvasive Pulmonary Aspergillosis in
Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,
More informationTurkish Thoracic Society
Türk Toraks Derneği Turkish Thoracic Society Turkish Thoracic Society Pocket Books Series Diagnosis and of Pneumonia in Immunocompromised Children Short Version (Handbook) in English www.toraks.org.tr
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationPneumonia in the Immunocompromised Host
SIOP PODC Supportive Care Education Presentation Date: 26 th October 2015 Recording Link at www.cure4kids.org: https://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p1bk39ernlb Pneumonia in
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationEffect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR814752Original ArticleOutpatient Treatment of Febrile NeutropeniaCosler et al. Volume 8 Number 1 2005 VALUE IN HEALTH Effect of Outpatient
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationHow to prevent Infections in Patients undergoing allo-hsct?
How to prevent Infections in Patients undergoing allo-hsct? Olaf Penack EBMT Course, 29 Sept 1 Oct 2014, Naples, Italy #EBMT2014 www.ebmt.org Prevention of Infections Epidemiology and risk factors for
More informationReference No: SG 23/13
Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,
More informationNonabsorbable Antibiotics
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1978, p. 958-964 0066-4804/78/0013-0958$02.00/0 Copyright 1978 American Society for Microbiology Vol. 13, No.6 Printed in U.S.A. Infection in Acute Leukemia
More informationDetection of Cytomegalovirus, Epstein-Barr Virus and Human Herpes Virus 6 and 7 DNA in Febrile Children with Cancer
Human Journals Research Article December 2016 Vol.:5, Issue:2 All rights are reserved by Daniel Thome Catalan et al. Detection of Cytomegalovirus, Epstein-Barr Virus and Human Herpes Virus 6 and 7 DNA
More informationClinical characteristics and therapeutic outcome of patients with febrile neutropenia: Our clinical experience
International Journal of Clinical Medicine Research 2014; 1(1): 26-30 Published online April 30, 2014 (http://www.aascit.org/journal/ijcmr) Clinical characteristics and therapeutic outcome of patients
More information8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications
Dean Van Loo Pharm.D. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Steroids Biologics Antineoplastic Most data from cancer chemotherapy Bone marrow suppression Fever is the
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationIndre Vengalyte MD¹, Regina Pileckyte MD¹, Laimonas Griskevicius MD PhD 1, 2
ASPERGILLUS GALACTOMANNAN (GM) ANTIGEN IN THE BRONCHOALVEOLAR LAVAGE (BAL) FLUID FOR THE DIAGNOSIS OF INVASIVE PULMONARY ASPERGILLOSIS (IPA) IN HEMATOLOGICAL PATIENTS Indre Vengalyte MD¹, Regina Pileckyte
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationChanges in Etiologic Microorganisms in Thai Patients with Chemotherapy-Induced Neutropenia and Fever
Original Article Changes in Etiologic Microorganisms in Thai Patients with Chemotherapy-Induced Neutropenia and Fever Chonticha Auesomwang MD 1, Bundarika Suwannawiboon MD 2, Methee Chayakulkeeree MD,
More informationBeyond the Reflex Arc: An Evidence-Based Discussion of the Management of Febrile Infants
Beyond the Reflex Arc: An Evidence-Based Discussion of the Management of Febrile Infants Cole Condra, MD MSc Division of Emergency Medical Services Children s Mercy Hospital October 1, 2011 Disclosure
More informationOntario s Referral and Listing Criteria for Adult Kidney Transplantation
Ontario s Referral and Listing Criteria for Adult Kidney Transplantation Version 3.0 Trillium Gift of Life Network Adult Kidney Transplantation Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationImmunohistochemical Confirmation of Infections
Immunohistochemical Confirmation of Infections Danny A. Milner, Jr, MD, MSc, FCAP The Brigham and Women s Hospital Harvard Medical School Boston, Masschusetts USA Judicious Use of Immunohistochemistry
More informationChoc septique. Frédéric Pène
Choc septique Frédéric Pène Réanimation Médicale, Hôpital Cochin, AP-HP Université Paris Descartes Institut Cochin, Inserm U1016, CNRS UMR-8104, Département 3i No conflict of interest A 54 y.o. male patient
More informationEmpirical Treatthent of Febrile Neutropenia: Evolution of Current Therapeutic Approaches
S256 Empirical Treatthent of Febrile Neutropenia: Evolution of Current Therapeutic Approaches James W. Hathorn and Kirsten Lyke From Duke University Medical Center, Durham, North Carolina Administration
More informationdevelop invasive fungal infections. 1 4 The diagnosis of fungal infections is particularly difficult in immunocompromised
Bone Marrow Transplantation, (1997) 20, 39 43 1997 Stockton Press All rights reserved 0268 3369/97 $12.00 Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections
More informationControversies in management: prophylaxis or diagnostics
5 th Advances Against Aspergillosis Controversies in management: prophylaxis or diagnostics Caveats in the use of biological markers for early diagnosis Drosos E. Karageorgopoulos, MD Researcher, Alfa
More informationCHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement
CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement Evidence-Based Assessment of Diagnostic Tests for Ventilator- Associated Pneumonia* Executive Summary Ronald F. Grossman, MD, FCCP; and Alan Fein, MD,
More informationDr. Arghya Samanta PG-3 Department of Pediatrics
Dr. Arghya Samanta PG-3 Department of Pediatrics A 3 year old male K/C/O B-cell Acute lymphoblastic leukemia Undergoing induction phase of chemotherapy On day 23 of induction Presented with - high grade
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.
More informationCANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS
CANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand Learning Objectives Summarize national guidelines
More informationClinical profile of high-risk febrile neutropenia in a tertiary care hospital
Clinical profile of high-risk febrile neutropenia in a tertiary care hospital Mohan V Bhojaraja 1, Sushma T Kanakalakshmi 2, Mukhyaprana M Prabhu 1, Joseph Thomas 3 1. Department of Medicine, Kasturba
More informationPulmonary Disease in the Immunocompromised Host (Second of Two Parts)*
Subject Review Pulmonary Disease in the Immunocompromised Host (Second of Two Parts)* WALTER R. WILSON, M.D., FRANKLIN R. COCKERILL III, M.D., Division of Infectious Diseases and Internal Medicine; EDWARD
More informationAmerican Journal of Infectious Diseases 4 (4): , 2008 ISSN Science Publications
American Journal of Infectious Diseases 4 (4): 237-243, 2008 ISSN 1553-6203 2008 Science Publications Cefepime Monotherapy is as Effective as Ceftriaxone Plus Amikacin in Pediatric Patients with Cancer
More informationFungal infection in the immunocompromised patient. Dr Kirsty Dodgson
Fungal infection in the immunocompromised patient Dr Kirsty Dodgson Aims Discuss different types of fungi Overview of types of clinical infections Clinical Manifestations Fungus Includes Moulds Aspergillus
More informationB. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.
Pharmacology - Problem Drill 24: Antibiotics, Antifungal and Antiviral Drugs Question No. 1 of 10 1. reduces the replication of influenza A and B viruses by inhibiting viral neuraminidase. Question #01
More informationCNS Infections in the Pediatric Age Group
CNS Infections in the Pediatric Age Group Introduction CNS infections are frequently life-threatening In the Philippines, bacterial meningitis is one of the top leading causes of mortality in children
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationCefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients
Journal of Antimicrobial Chemotherapy (199) 2, Suppl. B, 151-16 Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients P. Eggimann 0, M. P. Glauser", M. Aoun*, F.
More informationIntroduction. Study of fungi called mycology.
Fungi Introduction Study of fungi called mycology. Some fungi are beneficial: ex a) Important in production of some foods, ex: cheeses, bread. b) Important in production of some antibiotics, ex: penicillin
More informationClinical Manifestations of HIV
HIV Symptoms Diane Havlir, MD Professor of Medicine and Chief, HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 2, 2013 1 Clinical Manifestations of HIV! Result from
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationLung Abscess due to Clostridium barati in a Patient with Invasive Pulmonary Aspergillosis ACCEPTED
JCM Accepts, published online ahead of print on 3 January 2008 J. Clin. Microbiol. doi:10.1128/jcm.02446-07 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01297.x Piperacillin tazobactam monotherapy in high-risk febrile and neutropenic cancer patients C. Viscoli 1, A. Cometta 2, W. V. Kern 3, R. De Bock 4, M. Paesmans
More informationAdvanced Pediatric Emergency Medicine Assembly
(+)Joan Shook, MD, FACEP Professor of Pediatrics, Baylor College of Medicine; Chief Safety Officer and Chief Clinical Information Officer, Texas Children's Hospital Advanced Pediatric Emergency Medicine
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationNeutropenic Fever 1 InpatientPediatric Treatment
Neutropenic Fever InpatientPediatric Treatment (Hematologic Cancers and Stem Cell Patients) te: This algorithm should not be used for patients receiving CAR cell therapy. Page of 8 Patient presents with
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationA prospective study of cefepime versus ticarcilline/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients
A prospective study of cefepime versus ticarcilline/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients Dr Anjum Naeem,Hassan Hameed,Bashir Ahmad,Muhammad Tahir Aziz,Yasser Hussain,Mansoor
More information